Details for Patent: 7,470,433
Summary for Patent: 7,470,433
| Title: | Formulations for transdermal or transmucosal application | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent such as estradiol. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Dario Norberto R. Carrara, Arnaud Grenier, Celine Besse, Stephen M. Simes, Leah M. Lehman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Antares Pharma IPL AG | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US11/693,988 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Delivery; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 7,470,433: Scope, Claim Analysis, Expiration, and Estradiol Gel Patent LandscapeUS Patent No. 7,470,433 covers estrogen-containing transdermal or transmucosal gels using ethanol or another C2-C4 alkanol, a polyalcohol, and a diethylene glycol monoalkyl ether permeation enhancer. The patent is directed primarily to estradiol gel formulations that exclude progestins and long-chain fatty excipients. Its commercial relevance is closely associated with estrogen gel products such as Elestrin. The core technical combination is:
The patent’s commercial blocking value depends on whether a competing product practices the claimed excipient combination, not merely whether it contains estradiol. What does US Patent 7,470,433 protect?The patent protects composition-of-matter claims directed to estrogen gels for delivery through skin or mucosal tissue. It does not claim estradiol as a molecule. Estradiol is an old active pharmaceutical ingredient. The claimed subject matter is the formulation architecture and excipient relationship. Claim 1 is the principal broad independent claim. A product must contain all of the following elements to fall within its literal scope:
The claim does not require a specific estrogen concentration, daily dose, carbomer grade, pH, or commercial delivery volume. Those limitations appear in dependent claims. How broad is independent claim 1?Claim 1 is broad because it covers a genus of estrogen gels rather than one specific formula. The claim reaches formulations containing:
The claim is narrower than a general claim to all estradiol gels. A formulation that uses estradiol but lacks diethylene glycol monoethyl ether would not literally satisfy claim 1. The same is true for a formulation containing a progestin, depending on how the “provided that a progestin is not present” limitation is construed. The phrase “substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters” creates an additional limitation. A competing product containing a small amount of a fatty excipient would require a fact-specific analysis of whether the amount is inconsistent with the claimed substantial absence. What formulations are protected by claims 2 through 12?Claims 2 through 12 progressively narrow the formulation by concentration, dose, excipient identity, and manufacturing composition.
Claim 12 is particularly important because it recites a formula containing:
The claim uses “alcohol” rather than expressly limiting the ingredient to ethanol. The specification and surrounding claims would be relevant to determining whether “alcohol” in claim 12 is limited by the C2-C4 alkanol language appearing elsewhere in the claim set. How do claims 13 through 18 differ from claims 1 through 12?Claims 13 through 18 form a second claim set with a narrower and more commercially recognizable excipient combination. Claim 13 expressly requires:
The key distinction is that claim 13 identifies the three principal vehicle components by name or specific class:
Claims 14 through 18 then narrow estrogen content, dosage, formulation percentages, and active ingredient. Claim 18 is the most detailed claim in this group. It covers a composition containing:
Claims 13 and 18 are more vulnerable to design-around than claim 1 because they specify ethanol, propylene glycol, and diethylene glycol monoethyl ether. A competitor could potentially avoid literal infringement by replacing one of those components, although the doctrine of equivalents would remain relevant. What is the likely claim construction of “monoalkyl ether of diethylene glycol”?The phrase generally covers compounds formed by etherification of one hydroxyl group of diethylene glycol with an alkyl group. Diethylene glycol monoethyl ether is the principal example and is commonly identified as Transcutol or ethoxydiglycol. Claim 13 and claim 18 remove much of the interpretive dispute by expressly naming diethylene glycol monoethyl ether. Claim 1 is broader because it covers the class rather than only the ethyl ether. A formulation using diethylene glycol monomethyl ether could potentially fall within claim 1 if the compound satisfies the claim construction and performs the claimed permeation-enhancing function. It would not necessarily satisfy claim 13 or claim 18, which expressly require the monoethyl ether. What is the significance of the “no progestin” limitation?The exclusion of progestins limits the patent to estrogen-only formulations. A combined estrogen-progestin product would have a non-infringement position against claims containing the express exclusion, assuming the product actually contains a progestin as part of the marketed formulation. This limitation separates the claimed formulations from combination hormone-replacement products containing estrogen plus progesterone or a synthetic progestin. It also creates a potential design-around route for products that combine estradiol with a progestin, although regulatory, clinical, and formulation considerations may make that route commercially unattractive. The exclusion also limits the patent’s relevance to estrogen-only products such as estradiol gels. It does not prevent infringement by a formulation that contains other non-progestin active agents unless those ingredients alter the claim analysis. What are the principal validity issues?The patent’s validity risk would turn on the prior art and prosecution history. The principal legal pressure points are predictable from the claim structure. Obviousness under 35 U.S.C. § 103The combination of ethanol, propylene glycol, carbomer, water, and a glycol ether permeation enhancer may be challenged as an obvious formulation optimization if earlier references disclose:
The strongest patentability argument would likely rely on the combined performance of the excipient system, including adequate estradiol delivery while avoiding odor and irritation attributed to long-chain fatty excipients. Unexpected permeation, stability, tolerability, or dose performance could support non-obviousness under the standards applied to pharmaceutical formulations. Written description and enablementClaims 1 and 4 cover broad estrogen and vehicle classes. A challenger could argue that the specification does not adequately support the full scope of every claimed estrogen, every C2-C4 alkanol, every polyalcohol, and every monoalkyl ether of diethylene glycol. The narrower estradiol claims are generally less exposed because the specification and examples appear directed to estradiol gel products. The broad Markush claims present a larger genus-support question. IndefinitenessPotentially disputed terms include:
The functional permeation limitation may be construed in light of the specification and testing data. “Substantially free” is not automatically indefinite, but the intrinsic record would be important in determining the quantitative boundary. Written errors and claim clarityClaim 13 contains the phrase “long-chain fatty” at the end of the exclusion, apparently omitting “esters.” That textual defect would likely be evaluated under claim-construction and correction principles. The surrounding language and corresponding claims may support correction if the intended meaning is apparent. The error could still create litigation leverage. When did US Patent 7,470,433 expire?The patent issued on December 30, 2008. Its enforceable term is governed by the 20-year term rules under 35 U.S.C. § 154, measured from the applicable nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other USPTO-recorded events [1]. Public patent records associate the patent with the BioSante estrogen-gel formulation program and an expiration period in the mid-2020s. The patent should not be treated as currently enforceable without checking the USPTO Patent Center record for the exact term-adjustment calculation and any recorded extension or disclaimer [2]. For commercial diligence, the relevant conclusion is that the patent’s remaining-life value is limited or exhausted, depending on the applicable term calculation and the date of review. FDA marketing exclusivity and patent enforceability are separate issues. FDA exclusivity does not extend the patent term, and patent expiration does not itself establish FDA approval of a generic product. What is the Orange Book status of the patent?The Orange Book identifies patents submitted by NDA sponsors and accepted for listing against approved drug products. Listing does not establish that every claim is valid or infringed. It creates a statutory certification framework for ANDA applicants under the Hatch-Waxman Act [3, 4]. For an estradiol gel product associated with this patent, the commercial questions are:
The patent is principally a drug-product or formulation patent. It is not a patent to the estradiol active ingredient itself. A listed formulation patent can require an ANDA applicant to make a Paragraph IV certification even when the active ingredient is old. What Paragraph IV challenge risks exist?A generic estradiol gel applicant seeking approval before listed patent expiry would generally evaluate four certification options:
A Paragraph IV notice can trigger patent litigation under 21 U.S.C. § 355(j)(5)(B)(iii). A timely infringement action can impose a 30-month stay of ANDA approval, subject to statutory exceptions [4]. For this patent, a Paragraph IV strategy would likely focus on:
Because the active ingredient is estradiol, an ANDA applicant would not face biosimilar requirements. The product would generally proceed under the generic-drug framework if it can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with the relevant topical/transdermal product requirements. What is the biosimilar risk for this patent?There is no conventional biosimilar pathway for estradiol. Estradiol is a small-molecule active ingredient, not a biological product. The relevant competitive pathway is an ANDA or, depending on product differences, a 505(b)(2) application. The patent therefore creates generic formulation risk rather than biosimilar risk. A 505(b)(2) applicant could rely partly on FDA findings for an existing estradiol product while introducing formulation or delivery differences. Such an applicant would still need to address listed patents and applicable exclusivity. How does US 7,470,433 compare with competing estradiol gel patent estates?Estradiol gel products do not necessarily share the same formulation or patent estate. Commercial products may differ in alcohol content, permeation enhancers, carbomer systems, metered-dose pumps, application volume, and labeling.
The most important competitive distinction is whether the product uses diethylene glycol monoethyl ether. That ingredient, combined with ethanol and propylene glycol, places a product closer to claims 13 through 18. What manufacturing and formulation barriers remain?The patent does not protect every manufacturing process for estradiol gel. It primarily protects the finished formulation. A manufacturer may avoid the patent while producing a clinically equivalent product through a different vehicle. Practical barriers include:
These technical requirements can create commercial barriers even after patent expiry. They are regulatory and manufacturing barriers, not substitutes for patent rights. What licensing deals and ownership issues affect the patent?Patent ownership and product commercialization are separate diligence issues. A patent may have been assigned, licensed, or included in a broader transaction involving the estrogen product, while the FDA application is held by a different entity. A complete ownership review should track:
The patent itself does not establish the terms of a license agreement. Public assignment records establish chain of title, but private license economics, royalty rates, field restrictions, and settlement terms may not be fully public. What litigation and settlement issues should generic entrants evaluate?A generic entrant should search federal litigation records for:
The most material litigation issue would be whether the accused product contains the same functional excipient combination. A product with estradiol alone is not enough for infringement. The plaintiff would need to prove each required formulation element or establish infringement under the doctrine of equivalents. What generic launch scenarios exist?Three launch scenarios are commercially plausible. Launch after patent expiryThis is the lowest litigation-risk route. The applicant can certify Paragraph II if the listed patent has expired, subject to any separate patents, exclusivity periods, pediatric extensions, or regulatory barriers. Paragraph IV launch after litigationThe applicant may launch after prevailing in litigation, obtaining dismissal, or benefiting from a statutory or court-imposed resolution. Exposure includes damages, an injunction, and potential launch disruption. Formulation design-aroundThe applicant can develop a gel that avoids at least one required limitation, such as:
A design-around must address both literal infringement and the doctrine of equivalents. It also must satisfy FDA requirements independently. How strong is the patent estate?The estate is strongest against an estradiol gel that substantially replicates the claimed ethanol, propylene glycol, diethylene glycol monoethyl ether, carbomer, and water system. Claims 13 and 18 are especially relevant to that product profile. The estate is weaker against:
The broadest claims provide scope, but their breadth increases potential exposure to prior-art, enablement, written-description, and indefiniteness challenges. Key Takeaways
FAQsDoes US 7,470,433 cover all estradiol gels?No. It covers estradiol gels only when they contain the required vehicle, permeation enhancer, gelling system, and other claim limitations. An estradiol gel using a different penetration enhancer may fall outside the literal claims. Is Transcutol the same as diethylene glycol monoethyl ether?Yes. Transcutol is a common trade name for diethylene glycol monoethyl ether, also known as ethoxydiglycol. Its presence is particularly important under claims 13 through 18. Can a generic use ethanol and propylene glycol without infringing?Potentially, but the answer depends on the complete formulation. If the generic also uses diethylene glycol monoethyl ether, a carbomer gel, estrogen, and the claimed concentration ranges, infringement risk increases substantially. Does FDA approval prove infringement of the patent?No. FDA approval addresses safety, efficacy, quality, and regulatory requirements. Patent infringement is determined under patent law by comparing the accused product with the properly construed claims. Does the patent cover estrogen patches?Generally no. The claims are directed to gel formulations for transdermal or transmucosal administration. A patch product would not ordinarily satisfy the gel limitation, although separate patents could cover patch technology. References
More… ↓ |
Drugs Protected by US Patent 7,470,433
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,470,433
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/EP00/07533 | Aug 03, 2000 | |
International Family Members for US Patent 7,470,433
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 030312 | ⤷ Start Trial | |||
| Austria | 355854 | ⤷ Start Trial | |||
| Austria | 356636 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
